🔗 Share this article

As America continues making historic adjustments to its immunization recommendations, a particular individual has emerged in a surprising turn: Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on Covid shots in the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Program

Public health authorities had intended to reveal sweeping changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would put the US out of alignment with many the world with no evidence for public health gain. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric vaccine recommendations in the US to become more in line with the Danish model, a country with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far comments, she has kept her attention on immunizations – usually the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been standard for previous directors of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a large organization. She lacks background in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with laws and regulations and the science of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and all of those have to be managed,” she said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major administrative element to the job, which supervises more than 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” Woodcock added.

Official Statement and Controversial Initiatives

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “questions rely on incorrect premises”.

“This background aligns with the responsibilities of her job,” the spokesperson said, pointing to the time Høeg spent counseling the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's controversial priority voucher program, a controversial rapid drug-approval program that apparently troubled her preceding directors. “By what process are these therapies being picked for this expedited pathway? Who takes the choices?” Howard asked. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards laxer rules of pharmaceuticals, aside from shots.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if problematic, past, some experts said. She released a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after Covid vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new government encompassed revising rules for recently developed shots and ending “unnecessary” immunizations, she stated after the election on a podcast. At the FDA, Høeg has according to sources floated the idea of excluding adolescent males from obtaining Covid vaccines.

“She is an complete dogmatist who commences with her conclusions and tailors the evidence to retrofit the data in a extremely deceptive, dishonest manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other skeptics, {like|